Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises...

Medical technologies group Norwood Abbey Ltd [ASX:NAL] advises that the commercialisation phase
of the needle-free injection system project is progressing.
During the past six months, the company has received unsolicited approaches, in relation to the
technology, from a number of sources. Preliminary discussions have been undertaken with a number
of parties.
The parties include prominent pharmaceutical groups, one medical consulting group and a number of
research hospitals, all of whom have expressed interest in the human applications of the technology.
Two groups have approached the company regarding veterinary applications of the technology.
The Company’s strategy is to enter into multiple arrangements with a range of partners. The needlefree
technology presents a unique platform for the safe and controlled delivery of compounds of all
kinds.
The Company will continue to provide information and/or demonstrations on a confidential basis to
the parties with a view to consummating the first commercial arrangements at the earliest possible
date.
Shareholders are reminded that major pharmaceutical groups undertake extensive due diligence,
including technical assessments and patent assessments, and their timeframes are usually
considerable.
Meanwhile, continued progress has been made at MIT with respect to proving up the required
parameters of the needle-free actuator. Recent developments have been the subject of separate
reports in the past three months.
To find out more about the Norwood group, visit www.norwoodabbey.com
For further information please contact:
Lula Liossi
Corporate Communications Manager
Norwood Abbey Ltd
+61-3-9770-0063